Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

PROTHENA CORP PUBLIC LTD CO Director's Dealing 2017

Jun 13, 2017

32782_dirs_2017-06-13_73dca05f-ba5c-4b18-b41c-1170c9b7ec8c.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Prothena Corp plc (PRTA)
CIK: 0001559053
Period of Report: 2017-06-09

Reporting Person: Zago Wagner M. (Chief Scientific Officer)

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Stock Option (right to buy) $6.41 2023-01-29 Common Stock (16000) Direct
Stock Option (right to buy) $20.17 2023-09-03 Common Stock (15000) Direct
Stock Option (right to buy) $29.81 2024-02-04 Common Stock (15000) Direct
Stock Option (right to buy) $27.81 2025-03-11 Common Stock (19000) Direct
Stock Option (right to buy) $34.61 2026-02-24 Common Stock (21000) Direct
Stock Option (right to buy) $55.00 2027-02-22 Common Stock (20000) Direct

Footnotes

F1: The original grant was for 36,000 shares, of which 20,000 shares have been exercised and sold. The remaining shares underlying the option (16, 000 shares) are fully vested and exercisable as of the date hereof.

F2: A portion of the shares (14,062 shares) underlying this option are vested and exercisable as of the date hereof. The remaining shares subject to the option (938 shares) vest in successive, equal monthly installments through September 3, 2017, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.

F3: A portion of the shares (12,500 shares) underlying this option are vested and exercisable as of the date hereof. The remaining shares subject to the option (2,500 shares) vest in successive, equal monthly installments through February 4, 2018, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.

F4: A portion of the shares (10,291 shares) underlying this option are vested and exercisable as of the date hereof. The remaining shares subject to the option (8,709 shares) vest in successive, equal monthly installments through March 11, 2019, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.

F5: A portion of the shares (6,562 shares) underlying this option are vested and exercisable as of the date hereof. The remaining shares subject to the option (14,438 shares) vest in successive, equal monthly installments through February 24, 2020, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.

F6: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on February 22, 2018 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.